DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

DBVT Operating Income

Profit from core operations after operating expenses, before interest and taxes.

DBV Technologies S.A.NASDAQ: DBVT

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$47.9M, compared with -$26.62M a year earlier. Trailing-twelve-month operating income was -$172.95M.

Context

  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 3 analysts of -$90.55M (+38.4%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$47.9M-6.3% QoQ
Last fiscal yearDec 2025
-$147.06M-22.0% YoY
LTMMar 2026
-$172.95M-49.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.0%+77.4%+157.4 pp
1 year-22.0%+38.4%+60.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(147.06M) USD
Year-over-year change
-22.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How DBVT compares with its peers on the latest reported figures

  • DBVT's LTM Mar 2026 operating income of -$172.95M is the 10th highest of the 11 companies compared; the peer median is -$75.7M.
  • Its year-over-year change of -49.4% is the 9th highest of 10, against a peer median of +13.3%.
DBVT Competitors Peer median
Operating Income for DBVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANROAlto Neuroscience, Inc.LTM Mar 2026$54.9M +178.5%——
AMRNAmarin Corporation plcLTM Mar 2026-$37.36M +60.7%—17.4%
CLLSCellectis S.A.LTM Mar 2026-$46M +13.0%—67.6%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$46.86M ———
ENGNenGene Holdings Inc.LTM Apr 2026-$68.65M +22.0%——
KRROKorro Bio, Inc.LTM Mar 2026-$82.76M +13.3%—2154.0%
ALTAltimmune, Inc.LTM Mar 2026-$96.92M +1.3%—269216.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$97.79M +15.9%——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$172.43M -63.7%——
DBVTDBV Technologies S.A.LTM Mar 2026-$172.95M -49.4%——
ANNXAnnexon, Inc.LTM Mar 2026-$205.06M -12.1%——
Peer median (excluding DBVT) -$75.7M+13.3%—1110.8%

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.71M4.8M15.73M00
Cost of Revenue9.27M20.3M06.81M17.67M
Gross Profit(3.57M)(15.5M)15.73M(6.81M)(17.67M)
Gross Margin-62.5%-322.9%100.0%——
Research & Development70.34M75.5M60.22M89.9M116.68M
Selling, General & Admin23.83M17.56M31.94M23.81M28.28M
Operating Expenses93.93M101.48M92.16M113.71M147.06M
Depreciation & Amortization8.38M20.3M13.16M6.81M7.73M
EBITDA(91.16M)(76.68M)(63.27M)(110.99M)(139.32M)
EBITDA Margin-1597.0%-1597.5%-402.3%——
Operating Income(98.61M)(96.63M)(76.43M)(120.53M)(147.06M)
Operating Margin-1727.6%-2013.1%-486.0%——
Interest Income521K406.29K3.71M2.73M601.86K
Interest Expense690K427K000
Other Income / Expenses424K427K3.71M2.73M600K
Income Before Tax(98.19M)(96.2M)(72.72M)(117.8M)(146.46M)
Pre-Tax Margin-1720.2%-2004.3%-462.4%——
Income Tax Expense(381K)70K7K(4.08M)491K
Net Income(97.81M)(96.3M)(72.73M)(113.72M)(146.95M)
Net Margin-1713.5%-2006.3%-462.4%——
EPS (Basic)(1.80)(1.25)(0.75)(1.20)(1.70)
EPS (Diluted)(1.80)(1.25)(0.75)(1.20)(1.70)
Weighted Avg Shares55.1M77.38M95.12M96.17M86.4M
Weighted Avg Shares (Diluted)55.1M77.38M95.12M96.17M86.4M

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.